Thus, a reduction in sclerostin concentration contributes to an increase in bone mineral density (BMD) [14], and anti-sclerostin monoclonal antibodies are currently used in the treatment of osteoporosis [15]. The gene discussed is SOST; the disease is osteoporosis.